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The use of Raman spectroscopy with Chemometric analysis has been well documented as 
an effective method for the identification of counterfeit pharmaceutical products. Due to an 
ongoing concern about the lack of transparency surrounding the manufacturing of generic 
pharmaceuticals in the US, this project aimed to examine the utility of the method for the 
differentiation of generic pharmaceuticals. A testing pool of six generic acetaminophen brands 
along with four unique samples of name brand Tylenol acetaminophen was obtained and 
representative tablets were characterized by Raman spectroscopy.  
The results showed certain observable variance between brands and manufacturing lots. 
Two brands were determined to contain a titanium dioxide (TiO2) coating, allowing for simple 
differentiation based on examination of the Raman spectra. The Raman spectra of brands in 
which TiO2 was not observed were analyzed using Principal Component Analysis (PCA) to 
examine the unique variance present in each brand. This revealed discrete groupings of lots and 
brands due to variance observable within the PCA projections. The project provides proof of 
concept for the differentiation of genuine articles by Raman spectroscopy and chemometrics and 
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1.1 Research Motivations and Goals 
Within the United States of America, the US Food and Drug Administration (US FDA) is 
responsible for the monitoring and oversight of all pharmaceutical research, development, and 
production. Every drug product in the US is registered with a National Drug Code (NDC) and 
the FDA regulates, approves, and documents all pharmaceuticals on the market. This is done in 
the hopes of ensuring all drug products have undergone significant testing to confirm their safety 
and efficacy. Additionally, by enforcing stringent manufacturing regulations for pharmaceuticals 
consistency and safety between manufacturing locations and times is maintained. However, 
despite the extensive reach of the FDA, certain unregulated products persist in reaching the 
market. One of the most prevalent sources of unregulated pharmaceuticals is the counterfeiting 
of genuine products.1  
Counterfeiting of pharmaceutical drug products is a common offense within the US and 
globally. The presence of counterfeits within the market is primarily a safety concern, as any 
counterfeit product may contain illicit and unsafe compounds and result in injury or death for the 
individual who takes it. This issue alone is significant enough to make counterfeiting a large 
regulatory concern, and a key focus of the FDA and similar administrations internationally. 
These governing organizations are responsible for the identification of counterfeit products and 
ensuring that they are accurately attributed to the source for legal action and accountability.1, 2  
However, the presence of counterfeit pharmaceuticals has additional ramifications on the 
pharmaceutical market, including causing deleterious impacts on the availability and cost of the 
drug product. The presence of a counterfeit product in the market may disrupt the supply and 
demand balance of the product, leading to manufacturing surplus or shortage, and corresponding 
artificial inflation or deflation of the drug cost.2 Economic and marketing analysts specializing in 
  2 
the pharmaceutical field attribute these issues to confusion within the supply chain, as the outside 
source of product (albeit counterfeit material) is undocumented and therefore obscures the true 
state of supply. 
The issue of supply chain tracing within the pharmaceutical industry has become of 
increased importance over the past year due to the ongoing COVID-19 pandemic, which has 
caused shortages and manufacturing interruptions for many products. In February of 2020, with 
the pandemic looming, several economic and marketing analysts in the pharmaceutical industry 
highlighted the issue of transparency surrounding the manufacturing of generic pharmaceuticals 
in the US, mainly focusing on the fact that the manufacturing location and company of these 
products is not public information.3 This article was a follow-up to one published in 2015, which 
had emphasized the same issue and requested that the FDA be authorized to publicize 
manufacturing information about generic products; however, no changes to policy have been 
made.3, 4 This creates an additional issue for analysts attempting to predict the supply and 
demand of pharmaceuticals as there can be no communication between manufacturers and 
analysts regarding the source of pharmaceuticals.  
When analyzing pharmaceuticals, identification of counterfeits and differentiation of 
counterfeits from genuine articles can be accomplished by a number of analytical methods. Most 
commonly, liquid or thin layer chromatography (TLC) and nuclear magnetic resonance (NMR) 
are used for this purpose.1, 2, 5 These methods are effective, and are especially useful for 
identifying deficiencies in active pharmaceutical ingredients (API) or the presence of impurities, 
which can be inert but unregulated excipients or unsafe compounds, but they also have some 
impactful limitations. One primary issue is that these methods are destructive, resulting in a total 
loss or reduction of sample quantity, which can limit retesting possibilities. Additionally, these 
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methods require substantial sample preparation, separation, purification, and analysis time, 
resulting in higher cost of analysis and delay in obtaining results.2  
To overcome these challenges, vibrational spectroscopy, such as near-infrared 
spectroscopy (NIR) and Raman spectroscopy, has been used as an alternative for identifying 
counterfeit pharmaceuticals. Vibrational spectroscopy alone has limited usefulness for assessing 
mixtures. However, when coupled with chemometrics, a multivariate data processing framework, 
its applications increase substantially. Several authors spanning the previous decade have 
reported that chemometric analysis of  spectroscopic data can distinguish genuine and counterfeit 
pharmaceutical products utilizing several different projection methods and attribute counterfeit 
tablets to a source when a reference is available.1, 2, 6, 7 The research has investigated a range of 
sample tablet sources and active ingredients, including acetaminophen and tadalafil, and 
successfully identified tablets from unlicensed sources and tablets beyond their expiration.2, 7, 8 
Tablets may display a reduction in API quantity, an increase in API heterogeneity, amorphous or 
polymorphic content, or impurities, all of which serve to create distinguishable variation in shifts 
or intensity of peaks in the Raman spectra.  
Vibrational spectroscopy combined with chemometric analysis has been well 
documented as a viable method for the analysis of both genuine and counterfeit 
pharmaceuticals.6, 7, 9, 10 Two main studies that served as support for the current work 
demonstrate this utility on samples of acetaminophen tablets. The first, a 2010 study, presented a 
successful application of NIR spectroscopy with principal component analysis (PCA) and 
hierarchical cluster analysis (HCA) for the distinction of genuine acetaminophen tablets from 
different countries of origin.9 Small variations in spectra were modeled as discrete groupings of 
different brands in the PCA model. The authors outline a procedure for the classification of 
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acetaminophen tablets of different sources based on polymorph composition using NIR and 
chemometrics. Samples were gathered from international name brands, including Tylenol from 
the USA and Panadol from the United Kingdom. Though this article successfully demonstrated 
proof of concept for distinction and classification of genuine acetaminophen tablets, additional 
investigation into similar methods was not observed elsewhere in the literature.9   
The general conjunction of vibrational spectroscopy and chemometrics appears often in 
investigations of counterfeit pharmaceuticals. The second study,  a key study to the motivation of 
the current work, utilized Raman spectroscopy with HCA in order to accurately distinguish 
between genuine and counterfeit acetaminophen tablets.6 This study also investigated different 
sample preparations, such as intact tablets versus ground tablets, and different strengths of 
genuine tablets from the same brand. While the most significant results were those of the genuine 
and counterfeit differentiation, promising results of genuine article differentiation were also 
observed.6  
 The ongoing issue of manufacturing transparency in generic pharmaceuticals, along with 
the increased need for the monitoring and tracing of pharmaceutical supply chains in the light of 
the COVID-19 pandemic, served as motivation for the investigation of the application of Raman 
scattering with chemometric analysis for the classification of acetaminophen tablets and 
differentiation of tablet brands and lots from generic and name-brand sources.3 
The goal of the work was to provide proof of concept for the use of Raman spectroscopy 
and chemometrics for the assessment of inter- and intra-brand variability of pharmaceutical 
products. To achieve this, replicate samples of acetaminophen from varying brands and 
manufacturing lots were analyzed via Raman spectroscopy and the resultant spectra were 
projected by PCA to determine if the method was able to distinguish between tablets of different 
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brands, between tablets of the same brand but different manufacturing lots, and between tablets 
of the same brand by different API strengths.  
1.2 Acetaminophen 
Acetaminophen, otherwise known as paracetamol, is an analgesic, or pain reliever, and 
cited as the most common fever reducer and pain reliever worldwide, used both alone and in 
tandem with other APIs.6, 11 Acetaminophen tablets are widely available, both domestically and 
internationally, from a range of name-brand and generic sources. Acetaminophen is most often 
obtained over-the-counter, but there are also over 25 million prescriptions written yearly in the 
US. The majority of prescriptions will be filled from generic sources rather than with name-
brand product. Name-brand acetaminophen within the United States is available as Tylenol, 






Figure 1. Acetaminophen structure. 
Acetaminophen, or N-acetyl-para-aminophenol (Figure 1), is a p-aminophenol derivative 
first synthesized in 1877 by Harmon Northrop Morse at Johns Hopkins University by the 
reduction of p-nitrophenol in glacial acetic acid.12 The compound exists in several forms of 
crystal structures.  One main crystal structure is a monoclinic polymorph (form I); however, form 
II (orthorhombic) can also be isolated at standard conditions and three additional forms exist at 
high pressure conditions.13 The monoclinic form is used for the production of acetaminophen 
tablets, however, the crystals alone exhibit poor compression behavior and therefore the pills are 
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produced by the tableting of monoclinic acetaminophen with various excipients in order to 
ensure proper molecular packing and tablet hardness.11 
Although industrial procedures are highly similar between manufacturers, there are 
several possible sources of variations in genuine acetaminophen tablets, which we may be able to 
detect using Raman spectroscopy. The variations are most likely to result from the differences in 
the amount and the kind of inactive ingredients between samples. All brands are likely to have 
some variations in inactive ingredients, or excipients, used in the manufacturing process. 
However, even within the same brand we can expect possible differences between manufacturing 
lots because many excipients are interchangeable. As mentioned above, the excipients mainly 
serve to produce a drug tablet with greater structural integrity and hardness while not affecting 
the physical and chemical properties of the API.11 A variety of excipients may be used 
interchangeably in manufacturing based on cost and availability.14 In fact, we can often see the 
drug label stating, “one or more of these ingredients may be present” among the inactive 
ingredients listed on the label. Thus, the inactive ingredients and their relative abundance within 
a specific manufacturing lot may vary. Considering the excipients within a standard 
acetaminophen tablet ranges from 10-20 wt. %, these variations in ingredients could contribute 
to slight variations in the Raman spectra. Another possibility is a degradation of ingredients in 
the tablet depending on the tablet age or storage conditions like temperature and humidity.15 This 
degradation may contribute to the variations in the composition of a drug tablet. 
 
1.3 Raman Spectroscopy 
Raman spectroscopy is best known for its usefulness as a chemical identification method 
that is applied to inorganic, organic, and biological materials. Samples can be analyzed 
nondestructively with minimal sample preparation by Raman spectroscopy, which makes it an 
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ideal method for the rapid identification of compounds.16 Applications of Raman have 
significantly broadened over two decades in thanks to the lowered cost of instrumentation and 
the integration of imaging and spectroscopy systems to expand the method's utility.17, 18 Raman 
spectroscopy now holds a place not only in research laboratories, but also in forensics, 
manufacturing, agriculture, art history, medical applications and beyond.16 
 The basis of Raman spectroscopy is to collect and separate inelastic light scattering from 
molecules at wavelengths different from that of the incident light. This shift of wavenumber (or 
frequency) in Raman scattered light is called Raman shift and occurs due to interaction between 
the light and the vibrational modes of a molecule. Thus, the Raman shifts represent the 
vibrational frequencies of a molecule. A vibrational mode is said to be Raman active if an energy 
exchange with the incident light can result in a change of the polarizability of the molecule. The 
incident light will either be scattered at a lower energy, which will result in Stokes Raman 
scattering in which the scattered light has a longer wavelength, or scattered at a higher energy, 
resulting in anti-Stokes Raman scattering in which the scattered light has a shorter wavelength.16 
The Raman instrument is designed in order to allow for the collection of inelastically 
scattered light from molecules. The coupling of a Raman instrument with an optical microscope 
allows for precise location of a sample surface to collect Raman scattering signals, and 
construction of a depth profile of a sample if a confocal pinhole is adopted in the optical system. 
Thus, Raman microscopy belongs to chemical microscopic methods.  
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Figure 2. Schematic diagram of a Raman microscope. 
Figure 2 outlines a schematic diagram of a Raman microscope. A sample surface is first 
focused by controlling the distance between the sample and the objective lens, while the surface 
image is observed through an eyepiece or a charge coupled device (CCD) camera. Since Raman 
scattering intensity is intrinsically weak, a light source with strong beam intensity is required. 
Thus, the incident light source within a Raman instrument is typically a monochromatic laser in 
the visible or near-IR wavelength range. The laser beam is focused on the sample surface 
through the objective lens and the scattered light from the sample is collected through the same 
objective lens.  This scattered light is then passed through a notch filter which will remove 
Rayleigh scattering (elastic scattering) and transmit Raman scattering. Since Stokes Raman 
scattering is stronger than anti-Stokes Raman scattering, most commercial instruments are 
designed to detect Stokes Raman scattering. The inelastically scattered light that passes through 
the filter is sent to a grating which separates it into individual wavelengths of photons. These are 
then detected by a CCD detector and transcribed into a spectrum based on their intensity.  
  9 
Since the positions and the relative intensities of the Raman peaks of a molecule is 
unique depending on the molecular structure and chemical bonds, Raman spectroscopy can be 
used to identify a molecule. Raman spectroscopy and Fourier-transform Infrared spectroscopy 
(Ft-IR) are complementary techniques, both capable of obtaining structural information based on 
the vibrational modes of a molecule. While Raman activity requires a change in polarizability of 
the molecule, IR activity depends on a change in molecular dipole moment, so certain modes 
may be only IR-active or only Raman-active depending on the symmetry properties of 
vibrational modes. This makes each method suited for different applications.  
Raman spectroscopy has several key advantages over IR spectroscopy. First, the Raman 
bands are much sharper than the IR absorption bands, resulting in a better resolution of peaks. 
Second, the Raman spectroscopy is more useful for aqueous samples as water produces very 
weak Raman signals, while it shows strong absorption bands in an IR spectrum, which may 
interfere with analyte bands. The primary advantage for the current project is that the Raman 
scattering allows for the acetaminophen tablets to be tested in their intact form, while Ft-IR 
depends on light transmittance and therefore has thickness constraints that must be considered in 
sample preparation.16 Thus, Raman spectroscopy does not require special sample preparation 
steps.  
On the other hand, Raman analysis traditionally has limited discriminatory power for a 
sample that consisted of various mixtures, and is generally not useful for differentiating between 
similar samples when relying on direct comparison or library search. The ease of use and short 
analysis times still make Raman an ideal technique for many applications, therefore methods of 
expanding its practical utility are sought after.6, 16 The combination of Raman spectroscopy with 
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chemometric analytical methodology has been the subject of much research over the last several 
decades.6, 19 
1.4 Chemometric Analyses  
Chemometrics can be simply described as the integration of chemical analysis with 
multivariate statistical methods to expand and optimize experimental methodology. This system 
of statistical analyses is the result of multivariate theories developed alongside applied 
mathematics to functionalize data and strengthen the inferences researchers are able to make 
from it.4 A main catalyst of the development of chemometrics was the rapid growth of 
quantitative analytical chemistry throughout the late 19th and 20th centuries. This growth was 
driven by the development of instrumental analytical methods which generated an explosion of 
raw multi- or mega-variate data. This data was not reconcilable using traditional data processing 
methods and chemometrics played a key role in allowing researchers to meaningfully employ 
it.20 
Chemometrics was initially known as "chemical pattern recognition" prior to its formal 
designation and the methods are designed and adapted to investigate features of multivariate 
chemical data sets. Though quantitative analytical chemistry catalyzed its development, 
chemometric methods are broadly applied and useful in providing additional depth to studies in 
many fields.5 The successful application of chemometrics to a research study requires the study 
be designed with an awareness of the intrinsic link between the chemical data collection and the 
statistical framework that will be applied to present meaningful results. Chemometric studies 
generally proceed through five phases of analysis: design of experiments, sampling, data 
collection, data preprocessing, and data projection.20, 21 
Design of experiments (DOE) and sampling are the preparation and planning stages of 
the experiment, and both serve to ensure that the resulting data is representative and complete. 
  11 
DOE optimizes the analytical process while maintaining budgetary and time constraints on a 
study. In any experiment, specifically instrumental analyses, multiple parameters influence 
experimental results. When optimizing, testing across a range of each parameter is necessary, 
and ideally testing would be done as a parameter interaction matrix in order to avoid false 
maxima. However, when there are many parameters to test, testing each combination while 
varying one factor at a time is seldom feasible. DOE calculation creates a formalized design in 
order to minimize trials required to create a map of the experimental range to model how 
parameters interact. The design is done by coding each parameter range into ‘high’ and ‘low’ 
conditions and using software to create a range of experiments fitting an established framework 
to gather descriptive data.20, 22  
When DOE has established the experimental setup, the theory of sampling (TOS) 
provides a theoretical framework establishing appropriate sampling methods. Proper sampling is 
required to accurately characterize a population or heterogeneous material, and TOS ensures that 
samples are sufficient for representation. TOS encompasses two realms of sampling, physical 
and statistical. Physical sampling gathers samples from a heterogeneous source in order to 
establish mixing, composite, and heterogeneity. Statistical sampling involves sampling and 
resampling from multiple sources, lots, etc. to provide cross-validation and promote the 
development of classifications.15, 20 
The next step, data collection, is the chemical analysis portion of the process. After 
collection, raw data must be preprocessed prior to analyses to ensure accuracy and minimize the 
introduction of error in the projection process. Preprocessing methods are of two types" row-
wise and column-wise. Row-wise preprocessing methods are applied to all variables of a sample 
and include filtering, peak alignment, and baseline corrections. Column-wise preprocessing 
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involves application of the calculation to a specified variable across all samples. Examples of 
column-wise preprocessing include weighting, scaling, and centering.20 
The final phase is the data analysis utilizing chemometric projection methods in order to 
process and visualize the data. Analytical projection methods are designed for a variety of 
applications and can be used to demonstrate correlations, recognize patterns, classify results 
based on characteristic features, demonstrate consistencies, and identify distinguishing features 
of data that could not be shown by other methods. The type of projection method used depends 
on several features of the data including the number of variables, dimensionality, data type, and 
set size. The most common methods are multiple least squares regression, component analyses, 
predictive modeling, and multivariate classifications.20, 21 The coupling of Raman spectroscopy 
with chemometrics now has a wide range of established applications from cancer diagnosis to the 
discrimination of foreign fats and oils in dairy products.23, 24  
1.5 Principal Component Analysis (PCA) 
 
There are a number of chemometric projections with potential for the comparative 
analysis of pharmaceuticals including multiple linear regression (MLR), hierarchical cluster 
analysis (HCA), and principal component analysis (PCA).6, 9, 25 While each method has 
advantages, PCA was chosen for this work as it showed consistent success in the differentiation 
of similar samples with the characteristic peaks of a single component overwhelming the Raman 
spectra. PCA is generally appropriate for spectral data due to its reliance on the covariance of 
variables, making it capable of detecting small sources of variance, and its high power for 
dimension reduction creates a far easier interpretation than the raw, multi-variate data set.20, 26, 27 
In fact, the main focus of PCA is dimensionality reduction, which is accomplished by 
modeling sets of dependent variables in the sample data along single dimensions.26 This allows 
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for the reduction of the number of dimensions needed while still reflecting the majority of total 
variance within the raw data set. The dimensions calculated to represent each set of dependent 
data are termed principal components, or PCs. Each PC refers to a single dimension of the 
projection, which reflects one grouping of dependent variables. Each of these PCs is calculated 
as the linear combination of variables within the data set. The specific PCA projection depends 
on the number of PCs chosen for modeling, which will correspond to the total cumulative 
variance that is modeled by the PCA projection as a whole.27 
Each principal component is orthogonal, therefore, uncorrelated with the others, creating 
a basis set of dimensions in which to model the variance. The orthogonal components are 
calculated by performing an orthogonal decomposition of the data covariance matrix. The 
decomposition formula is shown in eq. 1.27 
 𝑋 = 𝑡1𝑝1
𝑇 + 𝑡2𝑝2
𝑇 + ⋯ + 𝑡𝑘𝑝𝑘
𝑇 + 𝐸   (eq. 1) 
The data matrix, X, is decomposed into vector components of loadings and scores and has 
dimensions of m samples and n variables. Loading vectors, pi, and scores vectors, ti, are 
calculated by determining the orthogonal basis of the matrix. The decomposition begins by 
determining the eigenvectors of the covariance matrix of X (eq. 2), which correspond to the 
loading vectors, pi. The covariance matrix is the representation of how each of the variables 
within the original data set, which contain linear dependence on each other, show dependent 
variance. 
 
      𝑐𝑜𝑣(𝑋) =  
𝑋𝑇𝑋
𝑚−1
     (eq. 2) 
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The eigenvectors of the covariance matrix are described as the ‘characteristic roots’ of 
the matrix, such that the product of a scalar (the eigenvalue, λ) and the eigenvector (pi) is 
equivalent to the product of the covariance matrix and the eigenvector (eq. 3).26, 27 
 
     𝑐𝑜𝑣(𝑋)𝑝𝑖 = 𝜆𝑖𝑝𝑖           (eq. 3) 
 
The eigenvalue is proportional to the amount of variance being captured by the 
dimension. The loading vector, a modeling single independent variable within the covariance 
matrix, then allows us to calculate the score vector via eq. 4, which is the projection of the data 
matrix onto the loading vector to yield the score vector for the dimension.  
 
      𝑡𝑖 = 𝑋𝑝𝑖     (eq. 4) 
 
Each pair of score and loading vectors represents a single principal component within the 
decomposition of the data matrix. The number of scores and loadings vectors in the 
decomposition depends on how many principal components are deemed necessary to model the 
meaningful variance within the data set. Any remaining variance not modeled by the PCs is 
captured in the error matrix, E.  
As suggested by their derivation, the loading vectors, pi, and score vectors, ti, describe the 
relationships between variables and samples, respectively. The loading vectors reflect how 
highly weighted a given variable is, or how much of the variance being modeled is observed at a 
given variable. The scores vectors indicate how strongly a sample is correlated with a given 
dimension. A sample which exhibits strong signal at variables with a high positive load will 
  15 
score strongly positively along that PC, while samples which display low signals at variables 
with a high positive load may score negatively along the PC.20, 27   
When performing PCA on spectral data, there is one phenomenon, generally only 
observed along PC 1, which results in the loading plot that resembles the sample spectra. This is 
because PC 1 captures the majority of the variance within the data set, which arises from the 
characteristic peaks of the compound(s) within the sample. The variables with the strongest 
signals will have the largest absolute variance, and therefore be more strongly loaded than those 
with lower signals. This resemblance of loading plots to the spectral data should not persist past 
the first PC, unless there are additional sources of known variance in the data, such as multiple 
chemical components each contributing characteristic peaks to the spectra.27  
II. Materials and Methods 
2.1 Acetaminophen Sampling 
A total of ten acetaminophen samples were purchased locally in order to test the intra- 
and inter-brand variability of the tablets.  To test inter-brand variability, six different extra 
strength tablet samples were purchased from generic brands, and to test intra-brand variation 
three replicates of extra strength Tylenol brand were purchased, each from a distinct lot, and one 
regular strength Tylenol brand sample was purchased for comparison. The extra strength tablets 
contain 500 mg of acetaminophen per tablet, and regular strength contains 325 mg of 
acetaminophen per tablet.  
The information of the tablets sampled, including their brand, the vendor, their NDC, 
weight, and API wt. % is summarized in Table 1. The inactive ingredients listings from each 
brand are included in Appendix 1. Three tablets from each sample were scanned by Raman 
microscope in order to examine possible intra-lot variation of the tablets.  
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Table 1.Physical and brand information of purchased acetaminophen tablets. 
 
2.2 Raman Method 
Raman spectra of all the samples were obtained with the confocal DXR Raman 
microscope (Thermo Fisher, Waltham, MA) equipped with a 780 nm diode laser, a CCD detector 
(2048 pixels), and an automated microscope stage. The set-up parameters for Raman microscopy 
were slightly modified from those used in others’ previous reports.9,28 Raman data were collected 
and processed using OMNIC software. We optimized the number of Raman scans (number of 
Raman spectra for average) and exposure time (detector integration time) considering both the 
signal to noise ratio (S/N) of Raman spectrum and total data acquisition time for a sample.  









TC 36800-484-62 Wegmans ODE2413 0.553 90.11 
Ready In 
Case 
RIC 59726-494-24 Walgreens H09800 0.612 80.32 
Walgreens Wal 0363-0175-08 Walgreens P119534 0.554 90.66 






OFE2816 0.553 89.08 
Up&Up UU 11673-838-05 Target C030G 0.556 89.63 
Tylenol SEA041 50269-449-35 
Family 
Dollar 
SEA041 0.61 81.1 
Tylenol SEA035 50269-449-35 Wegmans SEA035 0.607 82.5 
Tylenol SHA101 50269-449-35 
Dash's 
Markets 
SHA101 0.601 82.21 
Tylenol Reg 50580-495-01 Wegmans PMA121 0.389 83.32 
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Samples for analysis were placed on microscope glass slides and focused using a 10 
objective lens. The laser power was set to 2 mW.  The spectrograph aperture was set to 50 m 
slit width. The CCD exposure time was set to 4 s. The Raman spectrum of each sample was the 
result of averaging 32 exposures after the automatic background subtraction. For each tablet 
sample, three Raman spectra were collected at three different locations along the long axis of the 
tablet using the same instrumental parameters. Then, using an analysis tool in the OMNIC, these 
three Raman spectra were averaged to represent the composition of each tablet sample. 
2.3 Tablet Preparation  
Tablet samples were initially prepared in three different ways: pulverized powder, and 
tablet with and without a top coating layer. This was to establish the preferred method of sample 
preparation for further tests and to investigate if there were discernible differences in the Raman 
spectra of the samples that were prepared in different ways. 
The powder sample was prepared by pulverizing using a mortar and pestle and a small 
amount of the power was placed on a microscope slide to acquire its Raman spectrum. To 
remove the top coating layer of a tablet sample, the top surface was first ground using a coarse 
sandpaper and polished using a finer grade to smooth the surface. A sample of six tablets from a 
single lot of Tylenol brand acetaminophen were prepared as described above and tested for 
homogeneity using a 2-D Raman mapping, as suggested by Kwok and Taylor.7 Each point in the 
Raman map was gathered using a 4 s exposure time and 20 exposures in order to reduce 
acquisition time while maintaining an acceptable S/N. The 2-D mapping covered a 0.5 mm  0.5 
mm area, with scans at 0.1 mm intervals for a total of 25 points per Raman map.  
The Raman mapping experiments showed no distinguishing features between tablets of 
the same lot, and no visible variation in spectra gathered from the tablet form versus the 
  18 
powdered sample. Therefore, subsequent testing was performed using only tablet samples with 
and without the coating layer.    
2.4 Data Preprocessing 
Prior to any following data analysis, the wavenumber range of Raman spectra of all 
tested samples was adjusted to 35 - 1850 cm-1. Then, the baselines of the spectra were first 
corrected using the auto-baseline correction tool in the OMNIC software. Following correction, 
the spectra were overlaid to inspect any irregularities in the spectra caused by the correction. 
After the baseline correction, the Raman spectra obtained at three different locations on the tablet 
surface were averaged for further chemometrics analysis.  
In order to remove any non-significant variance within the data and improve the results of 
chemometric projections of the data, additional preprocessing of mean centering was performed. 
Mean centering is a column-wise preprocessing technique which is performed by subtracting the 
mean of a variable across all observations from that variable in each observation. When 
considering a group of Raman spectra, this is performed by subtracting the average signal 
intensity at a specific wavelength from the signal at the same wavelength across all replicate 
spectra.20 This forces a mean of zero for all variables and places all variables on the same scale, 
rather than having some being more highly weighted due to stronger signal intensities. Mean 
centering is appropriate for spectra data sets as it only considers equivalent variables, individual 
wavelengths, and does not depend on the data as a whole. Mean centering, and the following 
PCA projections, were performed on MATLAB using a PLS Toolbox chemometrics software 
package.  
2.5 Principal Component Analysis (PCA)  
The mean-centered Raman spectra were projected via a PCA method in order to more 
accurately and sensitively identify distinctions and groupings between tablets and brands. 
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Several data sets were created in order to test what combinations of brands and what ranges of 
wavenumbers within the Raman spectra were capable of producing the most robust classification 
of tablets and brands. Thirteen data sets prepared to build a PCA model are summarized in Table 
2. Four projections (data set #1 - #4) yielded useful information, and the results of each will be 
presented in the Results and Discussion section. The other data sets (#5 - #13) did not generate 
useful information and the results will not be discussed.  
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Table 2. Data sets for the PCA projection.  
Data set Tablet Preparation Brands Wavenumber Range 
#1 With top coating All 35 - 1850 cm-1 
#2 With top coating RIC and UU excluded 35 - 1850 cm-1 
#3 With top coating All 700 - 1850 cm-1 
#4 Without top coating All 35 – 1850 cm-1 
#5 With top coating All 1000-1850 cm-1 
#6 With top coating RIC excluded 35 - 1850 cm-1 
#7 With top coating RIC excluded 700 - 1850 cm-1 
#8 Without top coating All 700 - 1850 cm-1 
#9 Without top coating All 35 – 700 cm-1 
#10 Without top coating All 1000 - 1850 cm-1 
#11 Without top coating All 100 - 1850 cm-1 
#12 Without top coating All 150 - 1850 cm-1 
#13 Without top coating EQ excluded 35 - 1850 cm-1 
.  
  
  21 
III. Results and Discussion 
3.1 Intact Tablet Spectral Results 
The representative Raman spectra of 10 intact tablet samples, which were listed in Table 
1, were compared with that of standard acetaminophen powder as shown in Figure 3. The 
complete Raman spectra of all the tablets (three tablets per brand) are included in Appendix 2.  
Overall, the Raman spectra of intact tablet samples were identical to that of the standard 
acetaminophen except for the generic brands, such as Ready-In-Case (RIC) and Up & Up (UU). 
Even for the RIC and UU brands, both of them showed main Raman peaks of acetaminophen 
standards. This suggests that the Raman scattering signals of all tested tablets mainly result from 
the acetaminophen and additional Raman peaks arise from the inactive ingredients. It is 
interesting to observe that there were slight differences in the absolute Raman intensities of the 
active ingredient in the samples, which may have been contributed from different amount of 
active ingredient present in the tablet.  
There were noted discrepancies in the API wt. % among the tested tablet brands as shown 
in Table 1. There were two general groupings of brands. All Tylenol brands including both extra 
and regular strength had an API wt. % between 82-84%, while all generic brands except for RIC 
were close to 90 wt. % API. RIC was the only generic brand to have a similar API wt. % to that 
of the Tylenol brand samples. In general, the intensities of Raman bands that correspond to the 
acetaminophen appeared weaker in the tablets with 80 wt. % API than in those with 90 wt. % 
API as shown in Figure 3. On the other hand, there were no other distinctions on the Raman 
spectra as a result of the differences in API wt. %. Although the wt. % of excipients took up as 
high as 20 % of the weight of a tablet, the Raman peaks of these inactive ingredients did not 
appear because they consisted of small amounts of various compounds.   
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As mentioned above, the RIC and UU tablets showed more peaks than other tablets 
below 700 cm-1. We suspected that these two generic brands may have a top coating layer 
different from other brands. To characterize the additional Raman peaks, the Raman spectra were 
collected of the RIC and UU tablets without the top coating layer. These scans of the interiors of 
the tablets were subtracted from the corresponding Raman spectra of the two brands with the 
coating layer. The representative result of the subtraction for the RIC is shown in Figure 4 and 
shows four main peaks, all appearing below 700 cm-1. A similar result could be obtained for the 
UU. Performing a library spectral search identified the spectra as TiO2, a conclusion further 
supported by the peak positions being highly consistent with those reported in the associated 
literature as presented in Table 3. The presence of TiO2 as an ingredient is expected as it is 
present in the excipient lists for those the UU and RIC brands. The extra strength Tylenol 
replicate lots also include TiO2 as an inactive ingredient but the Raman spectra did not exhibit 
the same peaks, likely due to the TiO2 being homogeneously distributed throughout the tablet 
rather than in the coating layer. A small wt. % of TiO2 distributed throughout the tablet would 
not appear strongly in the Raman spectrum, and therefore was not observed.  
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Figure 3. Representative Raman spectra of the intact acetaminophen tablet samples. 
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Figure 4. Results of the subtraction of the Raman spectra of the interior of a RIC brand tablet 
from that of the Raman spectra of the same intact tablet. 
 
Table 3. Raman peaks of TiO2 standard
29 and those observed in Figure 4. 
TiO2 Observed Peaks 
144 cm-1 142 cm-1 
394 cm-1 394 cm-1 
514 cm-1 513 cm-1 
634 cm-1 637 cm-1 
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Comparison of each of the UU and RIC intact tablets revealed several points of interest 
resulting from the presence of TiO2 within the spectra. The 35 - 700 cm
-1 spectral range of the 
six tablets in which TiO2 was observed are overlaid with a common scale in Figure 5. A primary 
point of interest is the variation in signal intensity, both between the tablets of like brands and 
between the two brands.  
Figure 5. Raman spectra of all intact RIC and UU tablets tested.                            
 
The observed signal intensity between tablets of the same brand, while significant, was 
presumed to be due simply to inhomogeneity of the TiO2 coating on the tablets. Evidence to 
support this was found first by examining the three replicate scans along the long axis of each 
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tablet which were averaged to produce the representative tablet spectra. As shown in Figure 6, 
these individual scans for RIC Tablet 1 reveal that there is signal intensity variation across the 
length of the tablet. 
 
Figure 6. Raman spectra from three different locations along the length of a single RIC tablet. 
 
To determine if this intensity variation is the result of TiO2 inhomogeneity or photo-
degradation of the sample by repeated exposure to the laser source, a RIC tablet was scanned 
multiple times in the same location. The data showed that there was no reduction in signal, 
suggesting that there would be no photo-degradation of the sample upon repeated exposure to the 
laser for the adjustments of optics prior to the Raman measurements or during the Raman 
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scanning. Therefore, it is expected that the TiO2 coating varies in thickness both along individual 
tablets and between tablets of the same lot.  
Even in light of the range of intensity within the brands, there was a clear distinction 
observed between the intensity of the TiO2 peaks of RIC tablets and those of the UU tablets. The 
RIC tablets consistently presented higher signal intensity of TiO2, so that these characteristic 
peaks effectively masked the characteristic acetaminophen peaks in the region lower than 200 
cm-1. The UU tablets, however, showed lower TiO2 intensity and the characteristic 
acetaminophen profile is much more easily observed in these samples than in the RIC samples. 
These data suggest that they both use TiO2 as a top coating layer but the RIC has a thicker TiO2 
layer than the UU.  
Since the TiO2 appears in only two tablet samples of the ten different tablet samples, this 
Raman profile of TiO2 will contribute to a significant amount of independent variance. Based on 
the principles of PCA, this will be a likely convoluting feature. Two different approaches were 
attempted to see the dominant effect of TiO2 peaks. First, the RIC and the UU brands were 
removed from the data set.  Second, the wavenumber range of the Raman spectra in the data set 
was adjusted to exclude the characteristic Raman peaks of TiO2, so that the Raman signals only 
between 700 and 1850 cm-1 might be tested as shown in Figure 7.  
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Figure 7. Upper spectral range (700 - 1850 cm-1) of Raman spectra of intact acetaminophen 
tablets. 
 
In order to further examine this spectral range, and to determine the variance observed 
between tablets within the same brands, the variance of the three average spectra for each brand 
was calculated using OMNIC software. The variance of each brand spectra is shown in Figure 8, 
with the brands ordered by decreasing variance. Examining these variance results we observe 
that all of the name (Tylenol) brand tablets demonstrate lower variance between tablets than the 
remaining brands, with the exception of Family Wellness, the only generic brand to show similar 
variance levels. This indicates that the tablets of the Tylenol brand, both extra and regular 
strength, are more consistent within the manufacturing lots, while the generic brands are more 
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varied in composition. These trends within the variance spectra may be compared with the PCA 
score plot.  Larger variance between tablets is expected to correspond to a wider array of the 
tablets in the scores plots, whereas lower variance allows for closer groupings.  
 
Figure 8. Variance of the Raman spectra of the intact surface of three tablets for each 
acetaminophen brand, arranged in order of decreasing variance.  
 
3.2 Interior Tablet Spectral Results 
The Raman spectra of the interior of tablet samples were obtained after the top layer of 
the tablets was removed. The representative Raman data of the samples are shown in Figure 9. 
These spectra look all similar to each other, but is unsurprising as the characteristic Raman peaks 
of TiO2 of the two brands no longer appeared after the top layer of the tablets was removed. The 
Raman peaks in those spectra can be attributed to the active ingredients in the tablet. Although it 
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is not possible to differentiate the acetaminophen brands using this raw Raman data, it may be 
possible to do so by performing PCA projection on the Raman data.  
 
Figure 9. Representative Raman spectra for the interior surface of acetaminophen tablets from 
all acquired brands.  
 
The variance within the interior tablets was assessed in the same way as the intact tablet 
samples, however, in this case the entire spectral range (35 - 1850 cm-1) was examined. The 
results of the variance analysis are presented in Figure 10 and arranged in order of decreasing 
variance. There are some similarities in the trend between the variances of the Raman spectra of 
tablets with and without the coating layer, for example the Walgreens samples have the highest 
variance between intact tablets and the tablet interiors. However, there are also notable 
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differences in the rank order of the brand between the tablet interior scans and the intact tablets. 
The Tylenol brands are no longer grouped with similar variance, exhibit higher variance, and 
appear more inconsistent between lots in the interior than on the surface. Family Wellness tablets 
also appear to have much higher variance in their interiors, while Equate tablets have 
substantially lower variance. Overall, based on the variance results, the interior tablet scans 
should be more spread within the PCA space than the intact scans as there is a higher degree of 
variance between each tablet. This will be represented by distinct scores along the principal 
components.   
 
Figure 10. Variance of the Raman spectra of the interior surface of three tablets for each 
acetaminophen brand, arranged in order of decreasing variance.  
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The spread of tablets throughout the PCA scores plots is important for the model as the 
wider the range of scores for a certain brand is, the more likely it is to overlap with other brands 
scores along one or more PCs. This overlap, even slight, would limit the predictive power of the 
model; therefore, reducing the variance observed between tablets would be beneficial. The 
variance between tablets may be due to manufacturing, a proposition supported by the consistent 
low variance of the intact tablet scans of the Tylenol brand tablets, however the increased 
variance observed in the interior tablet spectra may be due to inconsistent tablet preparation for 
Raman measurements.  
Variance between tablets could be introduced by the tablet preparation in several ways. 
Firstly, since the tablets were hand-sanded to remove the coating layers, the tablet surfaces were 
likely not of a consistent surface texture. While the surfaces were smoothed and focused in the 
instrument, the possible inconsistencies of texture may have contributed to overall variance 
between the tablets. Second, again due to the sanding being done by hand, each tablet may have 
been sanded to a different depth. If the tablet composition was not fully homogenous throughout 
the depth of the tablet, the interior surface scanned would be different for each tablet, 
contributing to increased variance. These impacts could be tested by mapping a cross section of 
the tablet to determine if there was inhomogeneous composition, and mitigated by ensuring that 
all tablets have consistent surface texture prior to analysis.  
3.3 Intact Tablets: Full Spectral Range PCA 
 Data set #1 was compiled including all brands of intact tablet spectra and their full 
spectral range (35 - 1850 cm-1) for the PCA analysis. A total of three PCs were selected to model 
99.81 % variance within the data set based on the eigenvalue plot of this projection, as presented 
in Figure11. The full loadings and scores plots are provided in Appendix 3. The loading of PC 1 
for this model (Figure 12) highly resembles the Raman spectra of TiO2, with four main peaks 
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being highly loaded and very weak loadings of the remainder of the range. This indicates that the 
first PC is being overwhelmed by the unique variance being introduced by the TiO2 coating 
present on the RIC and UU tablets. The loading plot of PC 2, as shown in Figure 13, resembles 
the acetaminophen spectrum, signifying that PC 2 is the principal component that is capturing 
the variance of the acetaminophen itself. This large source of known variance introduced by the 
presence of TiO2 serves to overwhelm the first PC, and reduces the overall unknown variance 
that can be captured by the model. Only along PC 3, shown in Figure 14, did we observe 
unknown variance not reflecting the known components of the tablet samples.  
Solely based on the loading plots it is expected that the RIC and UU tablets will show 
unique scores, and these observations are confirmed in examining the scores plot of PC 2 vs. PC 
1 (Figure 15) in which the RIC and UU tablets are widely separated from the remaining brands 
along PC 1, and those remaining brands all score very closely on PC 1. The presence of the TiO2 
peaks leads to the high scores of RIC and UU tablets on PC 1, while the lack of these peaks in 
the remaining samples contributes to them scoring very consistently on PC 1. This overloading 
of PC 1 with the TiO2 variance limits the ability of this model to capture small sources of 
variance within the dataset. However, some more unique groupings can be observed in Figure 
16, which shows the scores plot of PC 3 vs. PC 2. This plot indicates that there is non-random 
grouping of brands together, and that tablets of like brands do more closely resemble their own 
brand than others. The most discrete groups were observed in the two of the extra strength 
Tylenol brand lots, SEA041 and SHA101, these showed unique scores on both PCs and were 
closely grouped. The Family Wellness and third extra strength Tylenol lot, SEA035, were not 
overlapping with other brands, however they showed a wide-spread between tablets, primarily 
along PC 2. The remaining brands all showed some degree of overlap with others. 
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Figure 11. Eigenvalue plot of the PCA projection of the intact Raman spectra for all brands. 
 
Figure 12. Loading plot of PC 1 of the PCA projection of the intact Raman spectra for all 
brands.  
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Figure 14. Loading plot of PC 3 of the PCA projection of the intact Raman spectra for all 
brands. 
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Figure 16. Scores plot of PC 3 vs. PC 2 of the PCA projection of the intact Raman spectra for all 
brands.  
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3.4 Intact Tablets: Full Spectral Range PCA with the RIC and UU Brands Excluded 
In order to remove the convoluting variance of the TiO2 in the Raman spectra, data set #2 
was compiled by removing the two brands in which the compound was observed from the intact 
tablet PCA data set. The resultant eigenvalues for the PC projection are shown in Figure 17, and 
based on this figure, three PCs were chosen for the model and 99.61% variance was captured. 
The loading plot of PC 1 (Figure 18) was noted to resemble the loading plot of PC 2 of the PCA 
model of data set #1 (see Figure 15), while PC 2 (Figure 19) loading resembled that of PC 3 of 
the same model (see Figure 16). The loading of the current model’s PC 1 resembles the 
acetaminophen spectra, while PC 2 and PC 3 (Figures 19 and 20) captured unknown variance 
within the data set.  
The resemblance of the loading plots of PC 1 and PC 2 to the previous model also led to 
the score projection of these two PCs, as shown in Figure 21, to resemble that of the 
corresponding projection of PC 2 and PC 3 of the previous model (see Figure 16). Due to these 
similarities, the score plot of PC 1 and PC 2 do not provide any new information about grouping 
the tablets, but when projected with PC 2 and PC 3, we are able to observe new discrete 
groupings of the tablet brands, as seen in Figure 22. This plot has clear and discrete groupings of 
three generic brands, Family Wellness, Equate, and Top Care, as well as discrete groupings of all 
three lots of extra strength Tylenol together near the center of the plot. The only significant 
overlap observed is the regular strength Tylenol and the Walgreens brand. However, when 
including PC 1 in the analysis we can see clear differentiation in these brands, as seen in the 3D 
projection of scores in Figure 23. These results indicate that with a more robust training set of 
tablets, it is likely we could reliably differentiate between each of the distinct tablet brands and 
lots.  
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Figure 17. Eigenvalue plot of the PCA projection of the intact Raman spectra for brands 
excluding RIC and UU.  
 
 
Figure 18. Loading plot of PC 1 of the intact Raman spectra for brands excluding RIC and UU. 
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Figure 19. Loading of PC 2 of the intact Raman spectra for brands excluding RIC and UU.  
 
Figure 20. Loading of PC 3 of the intact Raman spectra for brands excluding the RIC and UU. 
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Figure 21. Scores plot of PC 2 vs. PC 1 of the intact Raman spectra for brands excluding RIC 
and UU. 
 
Figure 22. Scores plot of PC 3 vs. PC 2 of the intact Raman spectra for brands excluding RIC 
and UU. 
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Figure 23. Three dimensional scores plot of PCs 1, 2, and 3 of the intact Raman spectra for 
brands excluding RIC and UU. 
 
3.5 Intact Tablets: Upper Spectral Range PCA 
The limitation of the previous model is that the brands in which TiO2 was observed had 
to be removed prior to the calculation in order to achieve the results. In order to account for all of 
the brands in a single model while excluding any influence from TiO2, data set #3, the upper 
spectral range (700 - 1850 cm-1) of the intact tablets of all brands, was used for the PCA 
projection. The eigenvalues for this projection (Figure 24) indicated the choice of three PCs in 
order to capture a total of 98.66% of the variance within the data set.  
The loading plot of PC 1 (Figure 25) resembles the upper range of the spectra, capturing 
the known variance within the sample, and the remaining PCs captured small sources of 
unknown variance. The 3D plots of the scores (Figures 26 and 27) show that the majority of the 
brands are grouped similarly to the model of data set #2, but with the RIC and UU brands are 
overlapping with each other as well as Equate, Walgreens, and Tylenol lot SEA035 tablets. This 
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overlap is in part due to the tablets being widely spread across the PC space, specifically along 
the PC 1. The source of this separation between tablets can be observed by examining the spectra 
of each of the tablets in which TiO2 was observed (Figure 5) and noting the inverse relationship 
between the Raman intensity of TiO2 peaks and the acetaminophen peaks. As PC 1 of this model 
is reflecting the known variance of the acetaminophen, the scores of the tablets along this 
dimension are dependent on the intensity of the acetaminophen peaks in the spectrum, so the 
variation in peak intensity between tablets created by the inhomogeneity of the TiO2 coating 
thickness directly impacts the PC 1 scores. These variations in intensity are still contributing to 
known variance caused by the presence of TiO2, although the characteristic peaks of this 
compound are not included. The 3D plots of the scores (Figures 26 and 27) indicate the distinct 
groupings of Family Wellness, Top Care, regular strength Tylenol, and extra strength Tylenol 
lots SEA041 and SHA101. The remaining brands showed overlapping scores, thus limiting the 
predictive power of this model. These results indicate the removal of the TiO2 peaks by limiting 
the spectra range was not sufficient to remove interference of the coating layer of the RIC and 
UU tablets. 
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Figure 24. Eigenvalue plot of the PCA projection of the upper range (700 - 1850 cm-1) Raman 
spectra of intact tablets for all brands.  
 
 
Figure 25. Loading plot of PC 1 of the PCA projection of the upper range (700 - 1850 cm-1) 
Raman spectra of intact tablets for all brands. 
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Figure 26. Three dimensional scores plot of PCs 1, 2, and 3 of the upper range (700 - 1850 cm-1) 
Raman spectra of intact tablets for all brands - View 1.  
 
Figure 27. Three dimensional scores plot of PCs 1, 2, and 3 of the upper range (700 - 1850 cm-1) 
Raman spectra of intact tablets for all brands - View 2. 
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3.6 Interior Tablets: Full Spectral Range PCA 
The PCA projection for the Raman spectra of the tablet interiors (data set #4) was 
generated in the hope that by using the interior scans, in which no TiO2 top layer was present, all 
brands could be discretely grouped and differentiated. The eigenvalues for the model are 
presented in Figure 28 and a total of three PCs were chosen in order to capture 99.38% of the 
total variance. The PC 1 loading (Figure 29) resembles the acetaminophen spectra as expected, 
while the remaining two PCs show unknown variance being captured (Figures 30 and 31). PC 3 
loading, as apparent in Figure 31, shows strong loadings in the low wavenumber range (35-150 
cm-1).  
The score plot of PC 2 vs. PC 1 (Figure 32) shows a non-random distribution of tablets, 
but no definable groups of any brands. All brands are overlapping along these two dimensions. 
Scores plots including PC 3 (Figures 33-34) show a unique score of the Equate tablets on PC 3. 
All three Equate tablets all show strong negative correlations along PC 3, creating a very distinct 
group. The Equate tablet spectra (Figure 35) showed no apparent unique signal which should 
produce these uncharacteristic scores within the lower wavenumber range and there was no 
unique Raman peak shifts or peak intensities observed. However, all other brands score very 
similarly along the model’s PC 3, indicating that there is a unique variance within the Equate 
tablet not present in the remaining brands. The close scores of all other brands along PC 3 also 
creates significant overlap between the brands on this dimension. 
This model has limited power for discrimination between brands as the delimitations of 
scores between tablets are more poorly defined. This is very likely a direct result of the increase 
in variance between spectra of the tablet interiors as compared to the intact tablet spectra. In the 
plot of PC 2 vs. PC 1 (Figure 32) there are few brands in which all tablets are grouped closely, 
namely Equate and regular Tylenol, while the UU, Walgreens, SHA101, SEA041, and FW 
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tablets are all widely spread across the PCs. These trends are consistent with the variance 
observed between tablets in Figure 10, as Equate and regular Tylenol show the lowest variance 
and the brands with the largest spread show the most. These brands showed closer groupings 
along PC 3, however this is in part an artificial effect of to the strong negative score of the 
Equate tablets along this dimension. 
Therefore, one method of potentially improving the model is by isolating the chemical 
source of the unique PC 3 scores of the Equate tablets, which was not accomplished in the 
current work. Based on the PC 3 loading plot for the model, it is clear that the unique variance 
occurs within the low range of wavenumbers, as the loadings are very strongly positive for 35 - 
100 cm-1. However, there are no clear distinction of the Raman spectra of Equate tablets in this 
range as compared to any of the other brands tested, therefore the precise cause of the variance is 
unknown. The difficulty in directly identifying the unique features is understandable as the third 
principal component is only capturing 0.74 % of the total variance in the model, therefore it 
follows that the specific features of the graph being represented may not be readily apparent. 
These small variations between brands would not be observable by direct comparison of the 
spectral data, but the PCA is able to model them as significant and allow for reliable distinction 
between the Equate tablets and other brands of acetaminophen tested. 
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Figure 29. Loading plot of PC 1 of the PCA projection of the Raman spectra of the tablet 
interiors for all brands. 
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Figure 30. Loading plot of PC 2 of the PCA projection of the Raman spectra of the tablet 
interiors for all brands. 
 
 
Figure 31. Loading plot of PC 3 of the PCA projection of the Raman spectra of the tablet 
interiors for all brands.  
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Figure 32.  Scores plot of PC 2 vs. PC 1 of the PCA projection of the Raman spectra of the 
tablet interiors for all brands.  
 
  
Figure 33. Scores plot of PC 3 vs. PC 1 of the PCA projection of the Raman spectra of the tablet 
interiors for all brands.  
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Figure 34. Scores plot of PC 3 vs. PC 2 of the PCA projection of the Raman spectra of the tablet 
interiors for all brands. 
 
 
Figure 35. Average Raman spectra for each Equate tablet scanned. 
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V. Conclusions and Future Directions  
This work represented the successful proof of concept of the use of Raman scattering 
spectroscopy with PCA chemometric projection for the differentiation of various brands and lots 
of genuine acetaminophen. A total of ten acetaminophen brand samples were tested using the 
method which was developed for the Raman scanning of the surface of intact acetaminophen 
tablets and the interior surface of the same tablets. The gathered Raman spectra did provide some 
useful information about the tablet brands, most notably the Raman scans of the intact tablets 
revealed the presence of a TiO2 layer on the surface of RIC and UU brand tablets, easily 
differentiating them from each other. Additionally, the peak intensity of the TiO2 varied 
significantly between the two brands, allowing them to also be differentiated from each other. 
The remaining tablet spectra were highly similar, making it difficult to differentiate the 
remaining brands, however the use of PCA of the spectra allowed the slight sources of variance 
within the spectra to be clearly modeled.  
 Revisiting the stated goals of the study, the PCA projections were, as a whole, able to 
achieve the desired results. Most promising, and revealing the most significant information, was 
the PCA model of the intact tablets, excluding the RIC and UU brands. This model, by excluding 
the known variance of TiO2 within the spectra, resulted in discrete groups of each of the 
acetaminophen tablets by brand, and differentiated manufacturing lots of extra strength Tylenol 
and the two strengths (regular and extra strengths) of Tylenol brand tablets. These groups were 
not tested for their predictive power; however, the use of a similar model for prediction should 
be a main goal for future work on this project. 
Any future studies performed on the basis of these results should also be adjusted to 
address some key limitations of this work. A main limitation is the number of brands tested and 
the lack of replicate lots of each of the generic brands. The results presented represent only 
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singular lots of the six generic brands, and therefore cannot be generalized to the product as a 
whole. Additionally, the method for Raman scanning should be adjusted in order to ensure non-
biased results. The current results were gathered by scanning all tablets of the same brand one 
after another, which may have created bias within scans and contributed to the grouping of 
tablets within the PCA. This possible bias could be minimized by creating a random order of 
tablet scanning so that all brands are not grouped, or by including an internal standard sample of 
acetaminophen in the sample set for normalization.  
Once a more accurate and representative data set has been acquired, the use of 
chemometrics should also be expanded by using additional projections and predictive tools in 
order to thoroughly test the power of the differentiation. The addition of hierarchical cluster 
analysis, boosted tree models, or multilinear regressions may all provide additional significant 
data and more clearly represent the variance for interpretation and prediction of tablet identity. 
Finally, models similar to those presented here may have potential to application to other 
pharmaceuticals and products. These applications could assist in consumer awareness, forensic 
applications, and product tracing. An overall increase in transparency surrounding 
pharmaceutical products is important as it allows the public to be more mindful and aware of 
their consumption, and manufacturers to hold themselves to a higher standard of consistency and 
safety. 
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Carnauba wax, corn starch*, croscarmellose sodium*, hypromellose, polyethylene glycol, povidone, 




Corn starch, croscarmellose sodium*, hypromellose*, lactose monohydrate*, magnesium stearate*, 
maltodextrin*, medium-chain triglycerides*, mineral oil*, polyethylene glycol polydextrose*, polyvinyl 
alcohol*, providone, purified water*, sodium starch glycolate*, stearic acid*, talc*, titanium dioxide. 
*contains one or more of these ingredients 
Walgreens Wal Castor oil, hypromellose, povidone, sodium starch glycolate, starch, stearic acid 
Equate EQ 
Carnauba wax, corn starch*, croscarmellose sodium*, hypromellose, polyethylene glycol, povidone, 




Carnauba wax, corn starch*, croscarmellose sodium*, hypromellose, polyethylene glycol, povidone, 
pregelatinized starch, sodium starch glycolate*, stearic acid. *contains one or more of these ingredients 
Up&Up UU 
Hypromellose, mineral oil, povidone, pregelatinized starch, sodium starch glycolate, stearic acid, 
titanium dioxide 
Tylenol SEA041 
Carnauba wax*, corn starch*, fd&c red no. 40 aluminum lake, hypromellose, magnesium stearate, 
modified starch*, polyethylene glycol*, powdered cellulose, pregelatinized starch, propylene glycol, 
shellac, sodium starch glycolate, titanium dioxide *contains one or more of these ingredients. 
Tylenol SEA035 
Carnauba wax*, corn starch*, fd&c red no. 40 aluminum lake, hypromellose, magnesium stearate, 
modified starch*, polyethylene glycol*, powdered cellulose, pregelatinized starch, propylene glycol, 
shellac, sodium starch glycolate, titanium dioxide *contains one or more of these ingredients. 
Tylenol Reg Magnesium stearate, modified starch, powdered cellulose, pregelatinized starch, sodium starch glycolate 
Tylenol SHA101 
Carnauba wax*, corn starch*, fd&c red no. 40 aluminum lake, hypromellose, magnesium stearate, 
modified starch*, polyethylene glycol*, powdered cellulose, pregelatinized starch, propylene glycol, 
shellac, sodium starch glycolate, titanium dioxide *contains one or more of these ingredients. 
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 Appendix 2  
Average Raman Spectra of Acetaminophen Tablets 
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TopCare Tablet Interior 
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Ready In Case Intact Tablets 
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Walgreens Intact Tablets 
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Equate Intact Tablets 
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Family Wellness Intact Tablets 
 
Family Wellness Tablet Interior 
  61 
 
Up & Up Intact Tablets 
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SEA041 Intact Tablets 
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SEA035 Intact Tablets 
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SHA101 Intact Tablets 
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Regular Intact Tablets 
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